Status:
TERMINATED
The Effect of Donepezil on Glycemic Control in Type II Diabetics
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
51+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to establish the effectiveness of the drug Donepezil in treating Type 2 Diabetes Mellitus compared to a control treatment. Donepezil is not approved by the FDA to treat Typ...
Detailed Description
The study is a randomized, double blinded, treatment-controlled, parallel design to investigate the effect of donepezil (administration of 5-10 mg of donepezil daily, orally, over 8 week period) on cl...
Eligibility Criteria
Inclusion
- Patients over the age of 50 with Type 2 Diabetes Mellitus, regardless of co-morbidities including renal and vascular insufficiency, Cardiovascular Autonomic Neuropathy, Hypertension, Chronic Obstructive Pulmonary Disease or Coronary Disease will be selected.
Exclusion
- Patients under the age of 50
- Patients who are pregnant or lactating
- Patients who are lactose intolerance
- Patients with an allergy to Donepezil
- Prothrombin Time and International Normalized Ratio value greater than 1.25
- Pre-menopausal women and patients allergic to Donepezil are excluded.
Key Trial Info
Start Date :
July 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 12 2023
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04507438
Start Date
July 12 2019
End Date
September 12 2023
Last Update
October 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Shore Regional Health
Easton, Maryland, United States, 21601